Our data suggest that pharmacologic approaches stimulating B55-dependent PP2A activity in the large pool of patients with PPP2R2A hemizygous deletions should be explored as a potential novel therapeutic strategy in PCa patients. The gene discussed is PPP2R2A; the disease is posterior cortical atrophy.